Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 6/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263702 | 0.90 | GBA1 (0.43) | RHOAGBA1GLATP53BP1USP30 | |
| SCHEMBL1263675 | 0.87 | GBA1 (0.46) | RHOAGBA1GLATP53BP1USP30 | |
| SCHEMBL4937383 | 0.86 | PIK3CA (0.48) | RHOAGBA1GLATP53BP1USP30 | |
| SCHEMBL1263690 | 0.84 | SCN9A (0.44) | RHOAGBA1GLATP53BP1USP30 | |
| SCHEMBL1262403 | 0.82 | MEN1 (0.42) | GBA1GLAMEN1KMT2A | |
| SCHEMBL1263343 | 0.78 | ITGA2B (0.49) | GBA1GLAMEN1KMT2A | |
| SCHEMBL1263685 | 0.77 | PTPN1 (0.45) | GBA1GLASCN9AMEN1KMT2A | |
| SCHEMBL1262935 | 0.76 | PTPN1 (0.44) | GBA1GLASCN9AMEN1KMT2A | |
| SCHEMBL1262989 | 0.74 | PTPN1 (0.50) | GBA1GLAMEN1KMT2A | |
| SCHEMBL4605845 | 0.74 | PTPN1 (0.50) | GBA1GLAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893063-B2 | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2011-02-22 | — | — | US | disclosed |
| US-20090143384-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | ASTRAZENECA UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143384-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, PIK3CB, TYMP | RHOA 2555/4885GBA1 2705/4885GLA 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.